Fig. 10From: De novo design and bioactivity prediction of SARS-CoV-2 main protease inhibitors using recurrent neural network-based transfer learningBoxplots of the performance of the classifier grouped by split method. The validation (red bars) and test (blue bars) sets consisted of random or scaffold-based splits of the original SARS-CoV-1 Mpro inhibitors dataBack to article page